Evommune Q2 2026: $288M Cash Funds Operations Through 2028; Key Phase 2b Data in September
EVMN sits 25% above its 52-week low of $10.47.
Summary
Evommune's Q2 2026 filing shows a strong cash position funding operations through 2028, with pivotal Phase 2b atopic dermatitis data for EVO756 expected in September 2026 — the next major value driver after the recent CSU trial failure.
Key Events · Earnings and Guidance · EVMN
-
Cash Runway Extended Through 2028
Cash, equivalents, and investments totaled $288.0 million at June 30, 2026, expected to fund operations through 2028 based on current plans.
-
Q2 Net Loss of $32.2 Million
Net loss was $32.2 million for Q2 2026 ($53.9 million for H1), driven by increased R&D spending on EVO756 and discovery programs.
-
Phase 2b Atopic Dermatitis Data in September 2026
Top-line results from the Phase 2b trial of EVO756 in moderate-to-severe atopic dermatitis are expected in September 2026 — the next major catalyst.
-
Migraine Trial Initiated, Results in 2027
A Phase 2b trial of EVO756 in migraine prophylaxis began in July 2026, with initial results expected in 2027.
Analysis · EVMN · Life Sciences
Evommune reported a Q2 net loss of $32.2 million, bringing the first-half loss to $53.9 million. The company ended June with $288 million in cash and investments, which management says funds the current plan through 2028 — a critical survival signal after the June failure of EVO756 in chronic spontaneous urticaria. The next major catalyst is top-line Phase 2b atopic dermatitis data for EVO756, expected in September 2026. A new Phase 2b trial in migraine prophylaxis began in July, with results due in 2027. The pipeline pivot is underway, but the stock trades at $13.11, well below the February private placement price of $27.88, reflecting the market's reset expectations.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVMN was trading at $13.11 on NYSE in the Life Sciences sector, with a market capitalization of approximately $481.9M. The 52-week trading range was $10.47 to $33.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.